Company profile
ORUKA THERAPEUTICS, INC.
NASDAQ:ORKABiotechnology: In Vitro & In Vivo Diagnostic Substances
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| AVRUKIBART | phase2 | — | 3 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (7)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07449702 | phase2 | recruiting | 2026-02-23 | 2030-05-01 | Oruka Therapeutics, Inc. | An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis |
| NCT07290569 | phase2 | active_not_recruiting | 2025-12-03 | 2027-06-01 | Oruka Therapeutics, Inc. | Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis |
| NCT07474792 | phase2 | recruiting | 2026-03-19 | 2027-10-01 | Oruka Therapeutics, Inc. | Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis |
| NCT07090330 | phase2 | active_not_recruiting | 2025-07-18 | 2026-03-25 | Oruka Therapeutics, Inc. | ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis |
| NCT06698939 | phase1 | completed | 2024-12-19 | 2026-03-13 | Oruka Therapeutics, Inc. | ORKA-001 in Healthy Volunteers |
FDA applications (0)
No records yet.